Shares of Aptinyx Inc (NASDAQ:APTX) have earned an average recommendation of “Buy” from the seven brokerages that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $14.00.
APTX has been the topic of a number of analyst reports. Zacks Investment Research upgraded Aptinyx from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research note on Wednesday, March 27th. Cantor Fitzgerald dropped their price target on Aptinyx from $18.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, March 22nd. Cowen restated a “buy” rating on shares of Aptinyx in a research note on Monday, June 10th. BMO Capital Markets restated an “outperform” rating on shares of Aptinyx in a research note on Friday, March 22nd. Finally, Svb Leerink assumed coverage on Aptinyx in a research note on Thursday, June 20th. They set an “outperform” rating and a $12.00 price target for the company.
APTX traded up $0.14 during trading hours on Thursday, hitting $3.29. The company’s stock had a trading volume of 437,677 shares, compared to its average volume of 378,309. The firm has a 50-day moving average of $3.33. Aptinyx has a 12 month low of $2.88 and a 12 month high of $32.25. The firm has a market cap of $106.05 million and a PE ratio of -1.25.
Aptinyx (NASDAQ:APTX) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.04). Aptinyx had a negative return on equity of 37.53% and a negative net margin of 1,166.40%. The business had revenue of $0.89 million during the quarter, compared to the consensus estimate of $1.00 million. As a group, analysts anticipate that Aptinyx will post -2.21 EPS for the current year.
In other news, Director Henry O. Gosebruch purchased 100,000 shares of the company’s stock in a transaction on Wednesday, May 8th. The stock was bought at an average cost of $3.86 per share, for a total transaction of $386,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 8.47% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. Great West Life Assurance Co. Can bought a new position in Aptinyx during the 4th quarter worth approximately $40,000. Gabelli Funds LLC bought a new stake in shares of Aptinyx in the 1st quarter valued at about $44,000. Alambic Investment Management L.P. bought a new stake in shares of Aptinyx in the 1st quarter valued at about $87,000. Metropolitan Life Insurance Co. NY raised its holdings in shares of Aptinyx by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock valued at $120,000 after purchasing an additional 5,652 shares during the period. Finally, Barclays PLC raised its holdings in shares of Aptinyx by 87.1% in the 4th quarter. Barclays PLC now owns 9,323 shares of the company’s stock valued at $154,000 after purchasing an additional 4,340 shares during the period. Institutional investors own 58.37% of the company’s stock.
Aptinyx Company Profile
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Further Reading: What is the Fibonacci sequence?
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.